A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors
This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Waihan Ho
- Telefonnummer: +65-96253244
- E-Mail: Waihan_Ho@henlius.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Able to provide written informed consent and comply with study requirements.
- Aged 18-75 years.
- Histologically or cytologically confirmed advanced or metastatic solid tumors following failure of standard treatment, or for which no standard treatment is available.
- At least one measurable extracranial lesion according to RECIST v1.1.
- ECOG performance status of 0-1 and life expectancy greater than 3 months.
- Willing to provide adequate archived tumor tissue or undergo a tumor biopsy.
- Adequate organ function;
- Agreement to comply with protocol-defined contraception requirements during the study and for at least 6 months after the last dose.
Exclusion Criteria:
- Other malignancies within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
- Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or live vaccination within protocol-defined washout periods.
- History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
- History or evidence of interstitial lung disease or other significant pulmonary conditions.
- Active infections, immunodeficiency, prior organ transplantation, or HBV/HCV infection meeting protocol-defined exclusion criteria.
- Significant cardiovascular, cerebrovascular, or thromboembolic disease.
- Brain metastases not meeting protocol-defined stability and eligibility requirements.
- Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
- Pregnancy or breastfeeding.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Dose Escalation
This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors. |
HLX105 will be administered as an intravenous(IV) infusion. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Dose-limiting toxicity (DLT)
Zeitfenster: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
|
|
Maximum tolerated dose(MTD)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Reaktionsdauer (DOR)
Zeitfenster: Bis ca. 2 Jahre
|
Bis ca. 2 Jahre
|
|
|
Number of participants with adverse events(AEs)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Number of participants with serious adverse events(SAEs)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Objective response rate(ORR)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Disease control rate(DCR)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Progression-free survival(PFS)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Overall survival(OS)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Cmax
Zeitfenster: Up to approximately 2 years
|
Maximum serum concentration (Cmax) of HLX105 |
Up to approximately 2 years
|
|
Tmax
Zeitfenster: Up to approximately 2 years
|
Time to maximum serum concentration (Tmax) of HLX105 |
Up to approximately 2 years
|
|
T1/2
Zeitfenster: Up to approximately 2 years
|
Half-life (T1/2) of HLX105 |
Up to approximately 2 years
|
|
Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells
Zeitfenster: Up to approximately 2 years
|
Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment. |
Up to approximately 2 years
|
|
Change From Baseline in Peripheral Blood Interferon Gamma Concentration
Zeitfenster: Up to approximately 2 years
|
Up to approximately 2 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HLX105-FIH101
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .